Medtronic (NYSE: MDT)+
announced today that the FDA granted 510(k) clearance for its MiniMed Go app for multiple daily injections (MDI).
A “unique” AI-powered headset that can predict epileptic seizures minutes before they occur has been developed by scientists in Scotland.
Researchers from Radboud University Medical Center and University of Basel have discovered new genetic causes of inherited blindness.
ESPOO, Finland, Jan. 8, 2026 /PRNewswire/ — HUS Helsinki University Hospital and VTT are starting a field test of wearable sensors to develop home dialysis. A total of 36 volunteer patients will use the sensors that enable monitoring of treatment effectivity. Making home dialysis safer and better would improve life quality and save society millions of euros annually.
MINNEAPOLIS, Jan. 8, 2026 /PRNewswire/ — Saluda Medical, Inc. (ASX:SLD, “Saluda” or the “Company”), a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel closed-loop neuromodulation platform, announced that, as expected, its next-generation EVA™ Sensing Technology has now received CE certification for commercialization in Europe with recognition of this approval in Australia. This follows FDA approval of EVA in December 2024.
Cold Spring Harbor Laboratory (CSHL) Professor Adrian Krainer’s lab discovered how the protein SRSF1 along with AURKA and MYC, jumpstart PDAC tumor development.
Some parts of our bodies bounce back from injury in fairly short order. The outer protective layer of the eye—called the cornea—can heal from minor scratches within a single day. The brain is not one of these fast-healing tissues or organs.
Peezy Midstream is available to Primary Care Providers, showing excellent clinical evidence around reduced false-positives and reduced specimen contamination evidenced by a Public Health Wales GP study, showing a 66% saving on lab spend.
Pain-sensing neurons in the gut kindle inflammatory immune responses that cause allergies and asthma, according to a new study by Weill Cornell Medicine.
A large-scale study has identified dozens of blood proteins linked to prostate cancer risk, some shared across populations, some unique to specific groups.